We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+41.21%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$89.7M
AUM Growth
-$8.98M
Cap. Flow
-$39.7M
Cap. Flow %
-44.23%
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$27.4M
2
IMDZ
Immune Design Corp.
IMDZ
+$16.1M

Top Sells

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$83.2M

Sector Composition

Rank Sector Weight
1 Healthcare 74.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
1
DELISTED
Audentes Therapeutics, Inc
BOLD
$32.2M 35.88%
+1,806,832
New +$27.4M
IMDZ
2
DELISTED
Immune Design Corp.
IMDZ
$16.7M 18.66%
+2,208,210
New +$16.1M
OCUL icon
3
Ocular Therapeutix
OCUL
$1.91B
$15.2M 16.97%
2,215,384
– –
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$14.7M 16.38%
407,416
– –
AKAO
5
DELISTED
Achaogen Inc
AKAO
$6.14M 6.84%
1,281,152
– –
GKOS icon
6
Glaukos
GKOS
$10B
$2.7M 3.01%
71,428
-2,515,557
-97% -$83.2M
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$2.03M 2.27%
1,048,601
– –

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return
CL
CRCM LP San Francisco, California $141M AUM 153.09% 1-Year Est. Return

Versant Venture Management's Q3 2016 Portfolio in Review

As of Q3 2016, Versant Venture Management held 7 positions worth $89.7M, down 9.1% from $98.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $39.7M in Q3 2016, reducing 1 holding. Its largest reduction was Glaukos, cutting an estimated $83.2M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 95% a quarter earlier.

Against the trend, Versant Venture Management opened a new position in Audentes Therapeutics, Inc worth $32.2M.

  • Versant Venture Management's largest Q3 2016 buy was Audentes Therapeutics, Inc: 1,806,832 shares worth $32.2M.
  • Versant Venture Management's biggest Q3 2016 reduction was Glaukos, cutting an estimated $83.2M.
  • Versant Venture Management's ten largest holdings make up 100% of its $89.7M portfolio in Q3 2016.
  • Versant Venture Management opened 2 new positions and closed 0 in Q3 2016.
  • Versant Venture Management's portfolio value fell 9.1% quarter-over-quarter to $89.7M.

Based on Versant Venture Management's 13F filing for Q3 2016, filed 24 Oct 2016.